Download Report: https://www.kuickresearch.com/report-global-bispecific-antibody-market,-drug-sales–and-clinical-pipeline-insight-2025.php
” Global Bispecific Antibody Market, Drug Sales & Clinical Pipeline Insight 2025″ Report Highlights:
- Applications of Bispecific Antibodies
- Global Bispecific Antibody Market Overview: Drug & Market Sales
- Global Bispecific Antibody Market Opportunity: US$ 8 Billion by 2025
- US & Japan Market Share Opportunity: >40% by 2025
- Bispecific Antibody Clinical Pipeline: 224 Drugs
- Commercially Available Bispecific Antibody: 2 (HEMLIBRA & Blincyto)
The market for bispecific antibodies is quiet bright as they are the new trends in the market. BsAbs due their specificity are gaining a lot of manufacturer’s interest. Now with the improved technology, monoclonal antibody therapy witnessed a drastic transition and is becoming more acceptable due to its site specific approach. They have become a critical component of clinical treatment procedure for a variety of indications. Currently there are 224 Bispecific Antibodies in clinical pipeline. Majority of Bispecific Antibodies are in preclinical phase followed by Phase-I clinical trials. At present there are 2 Bispecific Antibodies commercially available in the market.
Table of Contents
- History of Monoclonal Antibodies
- Overview of Bispecific Monoclonal Antibody
- Mechanism Of Action Of Bispecific Antibody
3.1 Trifunctional Antibody: Catumaxomab (Removab®)
3.2 Blinatumomab
- The Design & Engineering of IgG like Bispecific Antibodies
4.1 Quadroma (Hybrid Hydromas) Approach
4.2 “Knobs Into Holes” Approach
4.3 CrossMab Approach
4.4 Dual-Variable-Domain Immunoglobulin Approach
- The Design & Engineering of Small Bispecific Antibodies
5.1 Bispecific Diabodies
5.2 Bispecific T-Cell Engager Antibodies (BiTEs)
- Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies
- Applications of Bispecific Antibodies
7.1 BsMAb for Diagnosis of Infectious Diseases
7.1.1 Diagnosis of Bacterial Infections
7.1.2 Diagnosis of Viral Infections
7.2 BsMAb for Cancer Diagnostic
7.3 BsAbs Blocking Signaling Pathways
7.4 BsAbs Targeting Tumor Angiogenesis
7.5 Specific Delivery of Effector Compounds to Targets
7.6 Bispecific Antibodies & Gene Therapy
- Global Bispecific Antibody Market Overview
8.1 Current Market Scenario
8.1.1 Catumaxomab (Removab)
8.1.2 Blinatumomab
8.1.3 Duligotumab
8.1.4 SAR 156597
8.2 Global Bispecific Antibodies Clinical Pipeline Overview
- Global Bispecific Antibody Market Dynamics
9.1 Favorable Market Parameters
9.1.1 Target Patient Base
9.1.2 Severity Of The Disease
9.1.3 Unavailability Of Completely Curing Drugs
9.1.4 Side Effects of the Existing Drugs
9.1.5 Specificity of Monoclonal Antibodies in Targeting Cancer Cells
9.2 Commercialization Challenges
9.2.1 Stringent Regulatory Guidelines
9.2.2 Long Duration of Research & Development
9.2.3 Clinical Trial Timeline
9.2.4 High Cost for Research & Development
- Global Bispecific Antibody Market Future Prospects
- Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase
11.1 Research
11.2 Preclinical
11.3 Phase-I
11.4 Phase-I/II
11.5 Phase-II
11.6 Phase-III
- Marketed Global Bispecific Antibodies Clinical Insight by Company & Indication
12.1 Emicizumab (HEMLIBRA)
12.2 Blinatumomab (Blincyto)
- No Development Reported & Discontinued Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase
13.1 No Development Reported
13.2 Discontinued
13.3 Market Withdrawal
- Competitive Landscape
14.1 Ablynx
14.2 Adimab
14.3 Affimed Therapeutics
14.4 Amgen
14.5 AstraZeneca (MedImmune)
14.6 Chugai Pharmaceutical
14.7 Eli Lilly
14.8 EMD Serono
14.9 Emergent BioSolutions
14.10 Genentech
14.11 Genmab
14.12 Immunomedics
14.13 Jounce Therapeutics
14.14 MacroGenics
14.15 Merus
14.16 Neovii Biotech
14.17 NovImmune SA
14.18 OncoMed Pharmaceuticals
14.19 Pieris
14.20 Regeneron Pharmaceuticals
14.21 Roche
14.22 Sanofi
Contact:
Neeraj Chawla
Research Head
neeraj@kuickresearch.com
+911-9810410366